• 1
    Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62: 12636.
  • 2
    Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9: 45862.
  • 3
    Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released form human cancer cells. J Thromb Haemost 2004; 2: 20657.
  • 4
    Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 2007; 97: 114.
  • 5
    Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost 2006; 5: 704.
  • 6
    Tesselaar MET, Rominj FPHTM, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticles-associated tissue factor activity: a link between cancer and thrombosis. J Thromb Haemost 2006; 5: 5207.
  • 7
    Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA, Welterman A. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 11923.
  • 8
    Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13: 3627.
  • 9
    Combes V, Dignat-George F, Mutin M, Sampol J. A new flow cytometry method of platelet-derived microvesicle quantitation in plasma. Thromb Haemost 1997; 77: 21224.
  • 10
    Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998; 101: 5609.
  • 11
    Hemker HC, Giesen P, Al Dieri R, Regnault V, De Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 415.
  • 12
    Hemker HC, Beguin S. Thrombin generation in plasmas: its assessement via the endogenous thrombin potential. Thromb Haemost 1995; 74: 1348.
  • 13
    Sommeijer DW, Van Oerle R, Reitsma PH, Timmerman JJ, Meijers JCM, Spronk HMH, Ten Cate H. Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. Thromb J 2005; 3: 1221.
  • 14
    Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway – a model for rapid initiation of coagulation within the blood vessel. Thromb Haemost 2003; 89: 38.
  • 15
    Furie B, Zwicker J, LaRocca T, Kos C, Bauer B, Furie BC. Tissue factor-bearing microparticles and cancer-associated thrombosis. Haematol Rep 2005; 1: 58.
  • 16
    Hugel B, Martinez C, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology 2005; 20: 227.
  • 17
    Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45: 120208.
  • 18
    Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry 2007; 71A: 3845.
  • 19
    Jesty J, Beltrami E. Positive feedbacks of coagulation, their role in thresholds regulation. Arterioscler Thromb Vasc Biol 2005; 25: 24639.
  • 20
    Rand ML, Wang H, Bang KWA, Packham MA, Freedman J. Rapid clearance of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost 2006; 4: 16213.
  • 21
    Fontana V, Jy W, Dudkiewicz P, Horstman LL, Bidot C, Ahn Y. Cell-derived microparticles (C-MP) are elevated in splenectomized patients and depressed in those with hypersplenism, suggesting spleen as scavenger of C-MP. Blood 2006; 108: 428a.
  • 22
    Tiede MP, Ahn ER, Jy W, Scagnelli T, Bidot CJ, Horstman LL, Jimenez JJ, Ahn YS. Life-threatening hypercoagulable state following splenectomy in ITP: successful management with aggressive antithrombotic therapy and danazol. Clin Appl Thromb Hemost 2005; 11: 34752.